FeraMAX® Named #1 by Canadian Physicians and Pharmacists for Third Consecutive Year
May 02 2018 - 8:51AM
BioSyent Inc. (“BioSyent”) (TSX Venture:RX) is pleased to announce
that for the third consecutive year, FeraMAX® has been named
the #1 recommended iron supplement brand in a national survey of
Canadian physicians and pharmacists.
The 2018 OTC Recommendations Survey was
conducted by RK Insights and the following publications within the
EnsembleIQ Healthcare Group: Pharmacy Practice + Business, The
Medical Post, Profession Santé, CanadianHealthcareNetwork.ca, and
ProfessionSanté.ca. This annual survey was conducted online between
August 2017 and October 2017 with Canadian physicians and
pharmacists. In total, 1,649 surveys were completed by pharmacists
and 955 surveys were completed by physicians. FeraMAX® was named by
both pharmacists and physicians surveyed as the most recommended
iron supplement brand to Canadian patients.
“We are very pleased with the 2018 survey
results and the #1 recommendation for our FeraMAX® brand for the
third consecutive year,” commented Mr. René Goehrum, President and
CEO of BioSyent. “We are thankful that Canadian healthcare
providers have recognized the benefits of FeraMAX® in the treatment
and prevention of iron deficiency anaemia and continue to recommend
FeraMAX® to their patients.”
About
FeraMAX®
FeraMAX® 150 is an oral iron supplement
indicated for the prevention and treatment of iron deficiency
anaemia. This non-ionic polysaccharide-iron complex formulation
reduces adverse gastrointestinal side effects commonly experienced
with other iron formulations. A Vegan Certified formulation of
FeraMAX® 150 is also available in Canadian pharmacies and provides
an iron therapy option for vegans, vegetarians, and patients with
other dietary restrictions. FeraMAX® Powder, based upon the same
innovative non-ionic polysaccharide-iron complex technology found
in FeraMAX® 150, is available in a pleasant tasting, dissolvable
powder for pediatric patients.
For more information on FeraMAX®, please visit
www.feramax.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community, hospital
and international business units.
As of the date of this press release, the
Company has 14,509,095 common shares issued and outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
This press release may contain information or
statements that are forward-looking. The contents herein represent
our judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.Tel: (905) 206-0013E-Mail: investors@biosyent.comWeb:
www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024